Design Therapeutics, Inc. (DSGN)

Market Cap	310.28M
Revenue (ttm)	n/a
Net Income (ttm)	-47.78M
Shares Out	56.62M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,859
Open	5.47
Previous Close	5.48
Day's Range	5.34 - 5.51
52-Week Range	2.13 - 7.77
Beta	1.83
Analysts	Hold
Price Target	7.00 (+27.74%)
Earnings Date	Nov 7, 2024

About DSGN

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: DSGN
• Website: https://www.designtx.com

Analyst Forecast

According to 3 analysts, the average rating for DSGN stock is "Hold." The 12-month stock price forecast is $7.0, which is an increase of 27.74% from the latest price.

Price Target

$7.0

(27.74% upside)

Analyst Consensus: Hold